[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647486":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":52,"collaborators":25,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":25,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":25,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":38,"whyStopped":25,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Beijing Tiantan Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Control Group","ACTIVE_COMPARATOR","Participants in the control group will receive routine clinical care for chronic nonspecific low back pain.",[13],"Drug: Active Comparator #1",{"label":15,"type":16,"description":17,"interventionNames":18},"Toludesvenlafaxine Group","EXPERIMENTAL","Participants in the toludesvenlafaxine group will receive oral toludesvenlafaxine in addition to background care.",[19],"Drug: Toludesvenlafaxine",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","Active Comparator #1",[9],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Toludesvenlafaxine","Participants in the toludesvenlafaxine group will receive oral toludesvenlafaxine in addition to background care. Toludesvenlafaxine will be administered at 80 mg once daily. For participants with insufficient pain relief and acceptable tolerability, the dose may be cautiously increased to 160 mg once daily. The maintenance treatment period will be 3 months.",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Fang Luo","CONTACT","+8659976661","13611326978@163.com",[37],{"facility":32,"status":38,"city":39,"state":25,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Beijing","100050","China","CN",{"type":44,"coordinates":45},"Point",[46,47],116.39723,39.9075,{"lat":47,"lon":46},[50],{"name":32,"role":33,"phone":51,"phoneExt":25,"email":35},"59976661",{"type":53,"investigatorFullName":32,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Director of Department of Pain Management","100647486","toludesvenlafaxine-for-non-specific-low-back-pain-100647486",false,"NCT07709416","Toludesvenlafaxine for Non-specific Low Back Pain","Efficacy and Safety of Toludesvenlafaxine in the Treatment of Non-specific Low Back Pain","Inclusion Criteria:\n\n* Adults aged 18 to 75 years.\n* Diagnosis of chronic nonspecific low back pain, defined as pain located below the costal margin and above the inferior gluteal folds, lasting for more than 3 months, without a specific pathological cause.\n* Moderate to severe pain, defined as a Numerical Rating Scale score of 3 or higher.\n* Able to understand the study procedures and sign written informed consent.\n\nExclusion Criteria:\n\n* Low back pain caused by a known specific pathological condition, including but not limited to fracture, malignancy, infection, inflammatory disease, or other identifiable structural or systemic causes.\n* Major comorbidities that may interfere with study outcomes or represent contraindications to the study medication.\n* Current or previous diagnosis of depression, regardless of whether treatment was received.\n* Current or previous use of antidepressant medication.\n* Current use of opioid analgesics.\n* Pregnancy, breastfeeding, or planned pregnancy during the study period.\n* Known allergy, hypersensitivity, or contraindication to toludesvenlafaxine.\n* History of psychosis or other major psychiatric disorders.\n* Any condition that, in the investigator's judgment, makes the participant unsuitable for the study.","ALL","18 Years","75 Years",{"count":66,"type":67},132,"ESTIMATED","INTERVENTIONAL",[70],"NA","Chronic non-specific low back pain is the leading cause of productivity loss and disability worldwide, constituting a major public health challenge. This study aims to systematically evaluate and compare the role of the antidepressant drug toludesvenlafaxine in chronic non-specific low back pain, which is of critical importance for optimising clinical practice and developing precise, individualised treatment regimens.",[73],"Non-specific Low Back Pain",[27,73],"2026-07-24",{"date":77,"type":78},"2026-07-27","ACTUAL",{"date":80,"type":78},"2026-07-15",{"date":82,"type":67},"2028-12-01",{"name":5,"class":6},1]